VACC

Vaccitech plc [VACC] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

VACC Stock Summary

In the News

09:03 11 Dec 2023 VACC

Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B

OXFORD, United Kingdom, June 21, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics for the treatment of autoimmunity, chronic infectious diseases and cancer, will present positive final data from the HBV002 clinical trial at the European Association for the Study of the Liver (EASL) Congress 2023 – The International Liver CongressTM taking place June 21-24 in Vienna, Austria. HBV002 (NCT04778904) is a Phase 1b/2a clinical trial of VTP-300 in adults with chronic Hepatitis B (CHB). The data will be presented as a poster at EASL on Saturday, June 24 (Poster ID: SAT-198), by Eleanor Barnes, Professor of Hepatology and Experimental Medicine at Oxford University.

01:40 11 Dec 2023 VACC

7 Thrilling Biotech Stocks for Aggressive Investors to Buy

While it might be difficult to navigate the equities sector now amid various headwinds, biotech stocks to buy may offer a surprising respite. True, the market presence of the surprise production cuts by the Organization of the Petroleum Exporting Countries (OPEC) and non-member oil-producing nations — known as OPEC+ — along with the Federal Reserve's possible response.

04:30 11 Dec 2023 VACC

Vaccitech to Present at Upcoming October Investor & Scientific Conferences

OXFORD, United Kingdom, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Scientific Officer, Dr. Thomas G. Evans, Vice President, Corporate Development, Nick Fullenkamp, Senior Vice President, Synthetic Immunotherapies, Dr. Geoffrey Lynn, and Senior Research Development Scientist, Dr. Hugh Welles will be participating in the following conferences in October.

04:01 11 Dec 2023 VACC

Vaccitech to Present at Upcoming September Investors Conferences

OXFORD, United Kingdom, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will be participating in the following investment conferences in September.

01:33 11 Dec 2023 VACC

Vaccitech PLC Sponsored ADR (VACC) Upgraded to Buy: Here's Why

Vaccitech PLC Sponsored ADR (VACC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

01:48 11 Dec 2023 VACC

Vaccitech's Vaccine Induced Sustained Reductions In Hepatitis B Associated Antigens

Vaccitech plc (NASDAQ: VACC) announced an update to the interim analysis of safety and efficacy data from the HBV002 study evaluating ChAdOx1-HBV and MVA-HBV vaccines (VTP-300) in chronic HBV patients who are virally suppressed with oral anti-viral therapies. In the VTP-.

04:15 11 Dec 2023 VACC

Vaccitech to Present at the Jefferies Healthcare Conference

OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will participate in a fireside chat at the Jefferies Global Healthcare Conference at 8:30 a.m. EDT on Wednesday, June 8, 2022 in New York City.

11:30 11 Dec 2023 VACC

Vaccitech to Present at the H.C. Wainwright Global Investment Conference

OXFORD, United Kingdom, May 20, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will present at the H.C. Wainwright Global Investment Conference at 12:00 p.m. EDT on Tuesday, May 24, 2022. The conference will be held both in person in Miami and virtually.

07:57 11 Dec 2023 VACC

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Vaccitech (NASDAQ: VACC) is known to be the spin-off from Oxford University behind AstraZeneca Sars-Cov-2 vaccine.

08:00 11 Dec 2023 VACC

Vaccitech to Present at the Barclays Global Healthcare Conference 2022

OXFORD, United Kingdom, March 07, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced that the Company's Chief Executive Officer, Bill Enright, and Chief Financial Officer, Georgy Egorov, will participate in a fireside chat at the Barclays Global Healthcare Conference at 2:05 p.m. EDT on Tuesday, March 15, 2022, in Miami.

VACC Financial details

Company Rating
Buy
Market Cap
192.73M
Income
-77.26M
Revenue
7.26M
Book val./share
5.66
Cash/share
4.51
Dividend
-
Dividend %
-
Employees
33
Optionable
No
Shortable
Yes
Earnings
13 Nov 2023
P/E
-3.5
Forward P/E
-1.14
PEG
-9.85
P/S
14.36
P/B
0.88
P/C
0.7
P/FCF
-6.86
Quick Ratio
15.14
Current Ratio
15.26
Debt / Equity
0.06
LT Debt / Equity
0.06
-
-
EPS (TTM)
-2.04
EPS next Y
-2.76
EPS next Q
-0.71
EPS this Y
-107.11%
EPS next Y
35.29%
EPS next 5Y
24.51%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-40.32%
-
-
-
-
SMA20
-24.74%
SMA50
68.57%
SMA100
31.11%
Inst Own
19.57%
Inst Trans
0.76%
ROA
-22%
ROE
-23%
ROC
-0.28%
Gross Margin
100%
Oper. Margin
-494%
Profit Margin
-409%
Payout
-
Shs Outstand
38.55M
Shs Float
28.3M
-
-
-
-
Target Price
22
52W Range
1.64-5.1
52W High
-37%
52W Low
+215%
RSI
49.91
Rel Volume
-
Avg Volume
731.88K
Volume
3.1K
Perf Week
15.81%
Perf Month
0%
Perf Quarter
30.17%
Perf Half Y
33.47%
-
-
-
-
Beta
-0.274
-
-
Volatility
0.12%, 0.63%
Prev Close
10.53%
Price
3.15
Change
-0.63%

VACC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K
Revenue per share
0101.170.011.2
Net income per share
0-376.39-1.970.14
Operating cash flow per share
0-231.46-1.26-0.39
Free cash flow per share
0-237.61-1.3-0.55
Cash per share
0908.078.275.22
Book value per share
0-782.919.746.52
Tangible book value per share
0-774.718.055.44
Share holders equity per share
0-782.919.746.52
Interest debt per share
01.05K0.380.24
Market cap
0671.81K287.69M87.53M
Enterprise value
-9.65M3.77M80.85M-98.08M
P/E ratio
0-0.04-5.6316.39
Price to sales ratio
00.141.07K1.96
POCF ratio
0-0.06-8.83-6.07
PFCF ratio
0-0.06-8.53-4.26
P/B Ratio
0-0.021.140.36
PTB ratio
0-0.021.140.36
EV to sales
00.78301.7-2.19
Enterprise value over EBITDA
0-0.23-1.98-112.86
EV to operating cash flow
0-0.34-2.486.8
EV to free cash flow
0-0.33-2.44.77
Earnings yield
0-26.69-0.180.06
Free cash flow yield
0-16.85-0.12-0.23
Debt to equity
-0.08-1.240.030.04
Debt to assets
0.090.920.030.03
Net debt to EBITDA
0-0.195.06-213.59
Current ratio
2.836.2720.3217.4
Interest coverage
0-5.57-16.95-181.79
Income quality
00.610.64-2.71
Dividend Yield
0000
Payout ratio
0000
Sales general and administrative to revenue
02.1793.720.14
Research and developement to revenue
02.361.080.92
Intangibles to total assets
000.160.15
Capex to operating cash flow
00.030.040.43
Capex to revenue
0-0.06-4.28-0.14
Capex to depreciation
0-1.4-1.9-1.42
Stock based compensation to revenue
00.7561.520.22
Graham number
02.57K20.794.59
ROIC
0-1.88-0.17-0.08
Return on tangible assets
0-0.35-0.220.02
Graham Net
0-879.247.364.7
Working capital
10.5M40.26M215.61M200.8M
Tangible asset value
-22.08M-36.91M208.5M202.72M
Net current asset value
-24.87M-39.68M198.61M186.04M
Invested capital
-0.08-1.240.030.04
Average receivables
03.57M4.74M8.32M
Average payables
04.28M3.54M3.08M
Average inventory
0000
Days sales outstanding
0244.298.51K84.82
Days payables outstanding
0000
Days of inventory on hand
0000
Receivables turnover
01.490.044.3
Payables turnover
0000
Inventory turnover
0000
ROE
00.48-0.20.02
Capex per share
0-6.14-0.04-0.16

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
0.460.170.170.010.01
Net income per share
0.420.22-0.57-0.48-0.62
Operating cash flow per share
-0.230.32-0.3-0.08-0.44
Free cash flow per share
-0.280.25-0.32-0.15-0.52
Cash per share
5.175.375.225.034.51
Book value per share
6.846.556.526.145.66
Tangible book value per share
5.715.445.445.14.65
Share holders equity per share
6.846.556.526.145.66
Interest debt per share
0.230.250.240.210.32
Market cap
165.55M119.19M87.53M85.15M79.12M
Enterprise value
-18.16M-72.66M-98.08M-95.52M-81.73M
P/E ratio
2.643.62-1.03-1.17-0.83
Price to sales ratio
9.719.3313.56181.94236.89
POCF ratio
-19.7210.03-7.72-26.83-4.67
PFCF ratio
-15.8512.58-7.34-14.99-3.96
P/B Ratio
0.650.490.360.360.36
PTB ratio
0.650.490.360.360.36
EV to sales
-1.06-11.79-15.19-204.11-244.7
Enterprise value over EBITDA
-1.12-8.724.455.13.46
EV to operating cash flow
2.16-6.118.6530.14.82
EV to free cash flow
1.74-7.678.2216.814.09
Earnings yield
0.090.07-0.24-0.21-0.3
Free cash flow yield
-0.060.08-0.14-0.07-0.25
Debt to equity
0.030.030.040.050.06
Debt to assets
0.030.030.030.040.05
Net debt to EBITDA
-11.32-23.028.429.646.8
Current ratio
18.615.5817.416.7415.26
Interest coverage
208.917.32.37K7.83-1.88K
Income quality
-0.531.450.540.170.71
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
-0.38-1.813.1525.9439.31
Research and developement to revenue
0.521.71.8718.538.87
Intangibles to total assets
0.150.150.150.150.16
Capex to operating cash flow
0.24-0.20.050.790.18
Capex to revenue
-0.12-0.39-0.09-5.36-9.05
Capex to depreciation
-2.07-2.03-0.5-2.05-2.33
Stock based compensation to revenue
0.160.180.324.755.96
Graham number
8.065.719.138.148.88
ROIC
0.050.03-0.09-0.08-0.1
Return on tangible assets
0.060.04-0.09-0.08-0.11
Graham Net
4.964.854.824.363.96
Working capital
214.13M204.59M200.8M188.68M172.67M
Tangible asset value
212.29M202.46M202.72M193.88M178.57M
Net current asset value
196M187.29M186.04M172.42M156.11M
Invested capital
0.030.030.040.050.06
Average receivables
23.12M16.91M11.35M7.82M6.87M
Average payables
4.57M3.44M3.08M4.04M3.38M
Average inventory
7.71M8.92M6.89M2.94M0
Days sales outstanding
123.12153.07170.13661.732.78K
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
0.730.590.530.140.03
Payables turnover
00000
Inventory turnover
00000
ROE
0.060.03-0.09-0.08-0.11
Capex per share
-0.06-0.06-0.02-0.07-0.08

VACC Frequently Asked Questions

What is Vaccitech plc stock symbol ?

Vaccitech plc is a GB stock and trading under the symbol VACC

What is Vaccitech plc stock quote today ?

Vaccitech plc stock price is $3.15 today.

Is Vaccitech plc stock public?

Yes, Vaccitech plc is a publicly traded company.

Something similar

Top by Market Cap
Same Price Range
Similar Market Cap